CN1301108C - Metaducine dispersion tablet and its preparation method - Google Patents

Metaducine dispersion tablet and its preparation method Download PDF

Info

Publication number
CN1301108C
CN1301108C CNB2004100359415A CN200410035941A CN1301108C CN 1301108 C CN1301108 C CN 1301108C CN B2004100359415 A CNB2004100359415 A CN B2004100359415A CN 200410035941 A CN200410035941 A CN 200410035941A CN 1301108 C CN1301108 C CN 1301108C
Authority
CN
China
Prior art keywords
metadoxine
dispersible tablet
preparation
tablet
white tablets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB2004100359415A
Other languages
Chinese (zh)
Other versions
CN1650862A (en
Inventor
常建晖
徐文方
郑家晴
张建礼
王爱凤
王丽
张翠娟
崔美兰
邵义红
宋俊梅
周海洋
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Qingdao Pu Ruisen Pharmaceutical Technology Co Ltd
Original Assignee
Shandong Qidu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Qidu Pharmaceutical Co Ltd filed Critical Shandong Qidu Pharmaceutical Co Ltd
Priority to CNB2004100359415A priority Critical patent/CN1301108C/en
Publication of CN1650862A publication Critical patent/CN1650862A/en
Application granted granted Critical
Publication of CN1301108C publication Critical patent/CN1301108C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

The present invention provides a metadoxine dispersion tablet and a preparation method thereof. The metadoxine dispersion tablet comprises the following components: metadoxine, a filling agent, a disintegrating agent, corrigent, glidant and a lubricating agent. The preparation method comprises the following steps: raw materials and auxiliary materials are respectively ground by a sieve with 60 meshes for standby; the metadoxine, the filling agent, the disintegrating agent and the corrigent are evenly mixed; the lubricating agent and the glidant are added for evenly mixing; the metadoxine dispersion tablet is obtained through tabletting operation.

Description

Metadoxine dispersible tablet and preparation method thereof
Affiliated technical field
The present invention relates to a kind of dispersible tablet that contains metadoxine (Metadoxine) and preparation method thereof.
Background technology
Fatty liver, alcoholic liver become the second largest killer of hepatopathy after viral hepatitis.U.S. hepatopathy professional investigation mechanism found alcoholic liver crowd follow-up investigation through 4 years, the mortality rate of suffering from alcoholic liver and alcoholic fatty liver patient is much higher than the general population, serious symptom alcoholic fatty liver such as untimely treatment, most patients may be dead in some months.At present, owing to drink, the sickness rate of alcoholic liver and alcoholic fatty liver is also in rising trend in China.Its fearful part is that alcoholic liver and alcoholic fatty liver if untimely control meeting constantly worsens, make the patient go on the dead trilogy of alcoholic liver and alcoholic fatty liver → liver cirrhosis → hepatocarcinoma.
Metadoxine is developed by Italian LABORATORI BALDACCI S.P.A. company the earliest, has better curative effect for acute and chronic alcoholism of treatment and alcoholic liver disease.Metadoxine is an ion pair, has Benadon (vitamin B6) and 2-pyrrolidone-5-carboxylic acid (pyroglutamic acid: salt and covalently bound some characteristic of forming the cyclisation derivant of glutamic acid).Metadoxine is an aldehyde dehydrogenase activator, and the active of aldehyde dehydrogenase obviously increased.Experimental results show that in the presence of this product, acetaldehyde metabolism and the speed that changes into acetate are obviously accelerated, and can reduce the interact generation of the long-acting macromolecular complex that causes the tool cytotoxic activity of albumin and acetaldehyde, improve liver ATP concentration, accelerate amino acid whose transhipment in the cell, antagonism ethanol is to the inhibitory action of tryptophan pyrrolase, thereby accelerates the elimination of ethanol and acetaldehyde in blood and the urine, recovers liver function.Clinical acute and chronic alcoholism and the alcoholic liver disease of being used for the treatment of.
At present, the oral formulations that metadoxine goes on the market abroad has ordinary tablet and oral liquid, and specification is 500mg.The domestic preparation listing of still not having metadoxine.There is following problem in the metadoxine conventional tablet: the ordinary tablet volume is not big for (1) metadoxine, for the patient who swallows dysmasesis, uses inconvenience; (2) metadoxine is usually used in treating acute alcoholism, and ordinary tablet oral after, the disintegrate of medicine and principal agent stripping need a period of time, so onset is slow, bioavailability is low, thereby the metadoxine ordinary tablet is not suitable for the acute alcoholism patient; (3) metadoxine is usually used in treating alcoholic liver disease, needs long-term prescription, because metadoxine has intensive tart flavour, the ordinary tablet mouthfeel is bad, causes the long-term prescription difficulty, patient's poor compliance.Though there are not the problems referred to above in the metadoxine oral liquid, because volume is bigger, and glass bottle packing is frangible, and the patient carries inconvenience.It seems that generally existing metadoxine oral formulations can not satisfy treatment alcoholic liver disease and acute and chronic crapulent demand.Thereby needing a kind of new formulation of metadoxine, said preparation should have following characteristics: volume is little, is easy to carry; Be applicable to the patient who swallows dysmasesis; Rapid-action, bioavailability is high; Mouthfeel is good, is suitable for patient's long-term prescription.
As metadoxine being made dispersible tablet the problems referred to above are resolved, but have following difficulty: the very easily moisture absorption of (1) metadoxine, the dispersible tablet that adopts common preparation technology to make is against regulation disintegration, and easy moisture absorption deliquescence, is difficult for preserving; (2) the metadoxine crude drug is mobile poor, adopts common adjuvant to be difficult for making dispersible tablet; (3) the metadoxine specification is bigger, every 500mg, as adopt common adjuvant and prepared dispersible tablet, and need to add more adjuvant, cause the problem that tablet volume is big, cost is high.
The present invention makes dispersible tablet with metadoxine, and the problems referred to above are resolved.The metadoxine dispersible tablet is put into the low amounts of water jolting before use, and very fast disintegrate is dispersed into solution state, has the following advantages: (1) conveniently swallows patient's medication of dysmasesis; (2) solution state easily absorbs, and the bioavailability height is rapid-action, applicable to the acute alcoholism patient; (3) mouthfeel is good, is beneficial to improve patient's compliance; (4) volume is little, is easy to carry; (5) adopt Technology of the present invention to prepare the metadoxine dispersible tablet, used adjuvant amount reduces, and simplifies production technology, can reduce production costs.
Summary of the invention
The objective of the invention is at the deficiencies in the prior art, overcome the limitation of existing metadoxine preparation, provide a kind of absorptions soon, bioavailability height, application and metadoxine dispersible tablet easy to carry and preparation method thereof.
Purpose of the present invention is achieved by following testing program.
Metadoxine dispersible tablet of the present invention is composed of the following components: metadoxine 50~1000mg, filler 20~600mg, disintegrating agent 3~200mg, correctives 2~50mg, lubricant 0.2~40mg, fluidizer 0.5~20mg.
Described filler is selected from one of following formula or any two kinds or arbitrarily two or more mixture:
1. 2. 3. 4. microcrystalline Cellulose of mannitol of lactose of pregelatinized Starch.
Described disintegrating agent is selected from one of following formula or any two kinds or arbitrarily two or more mixture:
1. 2. 3. 4. 5. 6. 7. sodium lauryl sulphate of tween 80 of carboxymethyl starch sodium of crospolyvinylpyrrolidone of interlinkage sodium carboxymethyl cellulose of L-hydroxypropyl cellulose of microcrystalline Cellulose.
Described correctives is selected from one of following formula or any two kinds or arbitrarily two or more mixture:
1. 2. 3. 4. saccharin sodium of glycyrrhizin of aspartame of steviosin.
Described lubricant and fluidizer are selected from one of following formula or any two kinds or arbitrarily two or more mixture:
1. 2. 3. 4. 5. 6. stearic acid of sodium lauryl sulphate of Stepanol MG of micropowder silica gel of Pulvis Talci of magnesium stearate.
The preferred composition of metadoxine dispersible tablet of the present invention is:
Metadoxine 50~1000mg
Mannitol 20~600mg
Crospolyvinylpyrrolidone 3~200mg
Aspartame 2~50mg
Micropowder silica gel 0.2~40mg
Magnesium stearate 0.5~20mg
Preferred each set of dispense ratio was during above-mentioned metadoxine dispersible tablet was formed:
Metadoxine 500mg
Mannitol 250mg
Crospolyvinylpyrrolidone 50mg
Aspartame 16mg
Micropowder silica gel 24mg
Magnesium stearate 8mg
The composition of tablet can carry out suitable adjustment as required in the prescription, and the shape of tablet also can be adjusted as required, can be circle, ellipse, polygon or other special-shaped tablets.
The preparation method of above-mentioned metadoxine dispersible tablet, can adopt following two kinds of technologies to carry out:
1. direct powder compression, the preparation method of above-mentioned metadoxine dispersible tablet, carry out according to the following steps order:
(1) former, adjuvant is crossed 60 mesh sieves respectively, and is standby;
(2) with metadoxine, filler, disintegrating agent, correctives mix homogeneously;
(3) add lubricant and fluidizer, mixing;
(4) tabletting.Figure of tablet can be circle, ellipse, polygon or other all rational shapes.
2. compressing dry granulation, the preparation method of above-mentioned metadoxine dispersible tablet, carry out according to the following steps order:
(1) former, adjuvant is crossed 100 mesh sieves respectively, and is standby;
(2) with metadoxine, filler, disintegrating agent, correctives mix homogeneously;
(3) adopt rolling process or double compression to be pressed into sheet;
(4) sheet is pulverized, crossed 20 mesh sieves;
(5) add disintegrating agent, lubricant and fluidizer, mixing;
(6) tabletting.Figure of tablet can be circle, ellipse, polygon or other all rational shapes.
Metadoxine dispersible tablet of the present invention and preparation method thereof can produce following beneficial effect:
(1) the metadoxine dispersible tablet is put into the low amounts of water jolting before use, and very fast disintegrate is dispersed into solution state, conveniently swallows patient's medication of dysmasesis;
(2) solution state easily absorbs, and the bioavailability height is rapid-action, also is applicable to the acute alcoholism patient;
(3) mouthfeel is good, is beneficial to improve patient's compliance;
(4) volume is little, is easy to carry;
(5) adopt technique of direct powder compression or dry granulation tablet forming technique, avoid using organic solvents such as ethanol, and production technology is simple, is beneficial to suitability for industrialized production;
(6) adopt this method to prepare the metadoxine dispersible tablet, can reduce supplementary product consumption, reduce cost.
The specific embodiment
Can further clearly understand the present invention by specific embodiment given below and Application Example, but they not limitation of the invention.
Embodiment 1
Calculate by 1000 metadoxine dispersible tablet inventorys of preparation, the consumption of supplementary material is as follows:
Metadoxine 500g
Mannitol 250g
Crospolyvinylpyrrolidone 50g
Aspartame 16g
Micropowder silica gel 24g
Magnesium stearate 8g
Prepare the metadoxine dispersible tablet of above-mentioned prescription, carry out according to following steps:
(1) adjuvant is crossed 60 mesh sieves respectively, and is standby;
(2) with metadoxine, filler, disintegrating agent, correctives mix homogeneously;
(3) add lubricant and fluidizer, mixing;
(4) tabletting, promptly.Every contains metadoxine 500mg, and sheet heavily is about 0.7g.
Differentiate: contain similar phenolic hydroxyl structure in the metadoxine structure, can produce color reaction with ferric chloride.Method: get 20 of this product, porphyrize takes by weighing fine powder an amount of (being equivalent to metadoxine 100mg approximately), makes the principal agent dissolving with distilled water 10ml jolting, with 0.8 μ m filtering with microporous membrane, gets subsequent filtrate 1.0ml, adds 1 of FeCl3 test solution, and it is orange red that test solution shows.
Check:
Two appendix I of dispersing uniformity Chinese Pharmacopoeia version in 2000 A regulation dispersible tablet dispersing uniformity inspection method is as follows: gets two of dispersible tablets, puts jolting in the 100ml water, and in 20 ± 1 ℃ of water, all disintegrates and sieve (aperture 850 μ m) in 3 minutes by No. 2.
Other should meet pertinent regulations under the tablet item (two appendix I of Chinese Pharmacopoeia version in 2000 A)
Assay:
Chromatographic condition and system suitability test:
Chromatographic column: C18 post 250mm * 4.6mm, φ 5 μ m;
Mobile phase: second eyeball: 0.2% phosphoric acid (1: 99);
Detect wavelength: 205nm;
Flow velocity: 1ml/min;
Number of theoretical plate calculates by VB6 component peaks (peak 1) and pyroglutamic acid component peaks (peak 2) respectively all must not be lower than 3000.
Assay method: get 20 of this product, porphyrize, precision takes by weighing in right amount (being equivalent to metadoxine 50mg approximately), puts in the 100ml measuring bottle, adds mobile phase to scale, dissolving in ultrasonic 30 minutes, filter, precision is measured subsequent filtrate 10ml and is put in the 100ml measuring bottle, adds mobile phase and is diluted to scale, shake up, as need testing solution.It is an amount of that in addition precision takes by weighing the metadoxine that is dried to constant weight, is diluted to the solution of 50 μ g/ml, liquid in contrast with mobile phase.Precision is measured each 20 μ l of reference substance solution and need testing solution and is injected chromatograph of liquid, the record chromatogram, by external standard method with two component peaks areas with calculate content.Should be 90%~110% of labelled amount.
Indication: acute and chronic alcoholism, alcoholic liver disease.
Usage and dosage: put into before taking and take after the jolting of an amount of eliminating cold for resuscitation water is uniformly dispersed or oral, every day 2 times, each 1.
Specification: 500mg
Storage: lucifuge, protection against the tide, airtight preservation.
Embodiment 2
Except that prescription changed following composition into, other were with embodiment 1.
Prescription consists of:
Metadoxine 250g
Mannitol 150g
Crospolyvinylpyrrolidone 10g
Aspartame 6g
Magnesium stearate 6g
Micropowder silica gel 6g
Embodiment 3
Except that prescription changed following composition into, other were with embodiment 1.
Prescription consists of:
Metadoxine 500g
Mannitol 150g
Crospolyvinylpyrrolidone 20g
Aspartame 9g
Micropowder silica gel 14g
Magnesium stearate 8g
Embodiment 4
Except that prescription changed following composition into, other were with embodiment 1.
Prescription consists of:
Metadoxine 500g
Lactose 250g
Crospolyvinylpyrrolidone 50g
Aspartame 16g
Micropowder silica gel 24g
Magnesium stearate 8g
Embodiment 5
Except that preparation technology implemented according to the following steps, other were with embodiment 1.
Preparation technology presses step and implements:
(1) adjuvant is crossed 100 mesh sieves respectively, and is standby;
(2) with metadoxine, filler, disintegrating agent, correctives mix homogeneously;
(3) adopt rolling process or double compression to be pressed into sheet;
(4) sheet is pulverized, crossed 20 mesh sieves;
(5) add disintegrating agent, lubricant and fluidizer, mixing;
(6) tabletting, promptly.
Embodiment 6
Except that prescription changed following composition into, other were with embodiment 5.
Prescription consists of:
Metadoxine 250g
Mannitol 150g
Crospolyvinylpyrrolidone 10g
Aspartame 6g
Micropowder silica gel 6g
Magnesium stearate 6g
Embodiment 7
Except that prescription changed following composition into, other were with embodiment 5.
Prescription consists of:
Metadoxine 500g
Mannitol 150g
Crospolyvinylpyrrolidone 20g
Aspartame 9g
Micropowder silica gel 14g
Magnesium stearate 8g
Embodiment 8
Except that prescription changed following composition into, other were with embodiment 5.
Prescription consists of:
Metadoxine 500g
Lactose 250g
Crospolyvinylpyrrolidone 50g
Aspartame 16g
Micropowder silica gel 24g
Magnesium stearate 8g
Embodiment 9 metadoxine dispersible tablets and metadoxine sheet dispersing uniformity and dissolving out capability are relatively
1. get embodiment 1 metadoxine dispersible tablet and metadoxine sheet (Italian LABORATORIBALDACCI S.P.A. company, trade name: METADOXIL), check according to the dispersing uniformity inspection method: get two of this product, put jolting in the 100ml water, in 20 ± 1 ℃ of water, all disintegrates and in 3 minutes with crossing sieve No. 2.Write down complete disintegration time, the results are shown in Table 1.
Table 1 metadoxine dispersible tablet and metadoxine sheet dispersing uniformity check result
Preparation Disintegration
The metadoxine dispersible tablet 29 seconds
The metadoxine sheet 600 seconds
2. get embodiment 1 metadoxine dispersible tablet and metadoxine sheet (Italian LABORATORIBALDACCI S.P.A. company, trade name: METADOXIL), carry out the dissolution test according to following dissolution test method: sample thief, be dissolution medium with 900ml degassing distilled water respectively, temperature is 37 ℃, rotating speed is 50 rev/mins, operation in accordance with the law, and in 2,5,10,20,30,5ml (replenishing equality of temperature distilled water 5ml simultaneously) took a sample respectively in 45 minutes, 0.8 μ m microporous filter membrane filters, adopt the HPLC method to measure after getting subsequent filtrate dilution suitable multiple, calculate accumulative total stripping percentage rate relatively.Result of the test sees Table 2:
Table 2 metadoxine dispersible tablet and metadoxine sheet dissolution test result
Time (minute) 2 5 10 20 30 45
The metadoxine dispersible tablet 92.3 97.8 98.0 98.1 98.1 98.1
The metadoxine sheet 9.2 20.6 31.3 47.9 60.8 80.3
The above results shows: the disintegrate of metadoxine dispersible tablet of the present invention and dissolving out capability obviously are better than the metadoxine sheet, and disintegrate and stripping are the speed limit processes that oral formulations absorbs, so the metadoxine dispersible tablet can improve the infiltration rate and the bioavailability of medicine, thereby reach quick-acting, purpose efficiently.
Embodiment 10 metadoxine dispersible tablet stability tests
Get embodiment 1 metadoxine dispersible tablet and carry out stability study, comprising: accelerated test and long term test.
1. accelerated test
Sample was placed 6 months under 40 ℃ ± 2 ℃ of temperature, relative humidity 75% ± 5% condition by listing packing, respectively at 0,1,2,3, the every index of sampling and measuring in June, and with compared in 0 month.The results are shown in Table 3.
Table 1 accelerated test result
Lot number Time (moon) Appearance character Content (%) Related substance (%) Dispersing uniformity Dissolution (%)
030706 0 1 2 3 6 White tablets white tablets white tablets white tablets white tablets 100.24 100.79 99.56 101.21 100.07 0.27 0.25 0.30 0.20 0.24 Up to specification up to specification 98.03 97.48 96.72 96.91 96.50
030707 0 1 2 3 6 White tablets white tablets white tablets white tablets white tablets 98.50 99.12 99.37 98.16 99.09 0.31 0.30 0.26 0.33 0.19 Up to specification up to specification 97.06 97.46 97.23 96.63 96.55
030708 0 1 2 3 6 White tablets white tablets white tablets white tablets white tablets 101.48 100.16 101.69 100.75 100.91 0.33 0.22 0.35 0.23 0.26 Up to specification up to specification 98.19 97.33 97.56 96.76 95.68
The result shows: this product is compared with 0 month through accelerated test 6 months, and the every index of three batch samples has no significant change.
2. long term test
Sample was placed 6 months down in room temperature condition by listing packing, respectively at 0,3, the every index of sampling and measuring in June, and with compared in 0 month.The results are shown in Table 2.
Table 2 long-term test results
Lot number Time (moon) Appearance character Content (%) Related substance (%) Dispersing uniformity Dissolution (%)
030706 0 3 6 White tablets white tablets white tablets 100.24 101.03 100.70 0.27 0.20 0.33 Up to specification up to specification 98.03 97.15 97.60
030707 0 3 6 White tablets white tablets white tablets 98.50 99.15 98.76 0.31 0.23 0.27 Up to specification up to specification 97.06 97.20 96.96
030708 0 3 6 White tablets white tablets white tablets 101.48 101.02 100.97 0.33 0.26 0.23 Up to specification up to specification 98.19 97.83 96.57
The result shows: this product is through long term test 6 months, with 0 month relatively, the every index of three batch samples has no significant change.
Stability test is the result show, metadoxine dispersible tablet of the present invention has good stability.

Claims (2)

1, a kind of metadoxine dispersible tablet is characterized in that described metadoxine dispersible tablet is composed of the following components:
Metadoxine 50~1000mg
Mannitol 20~600mg
Crospolyvinylpyrrolidone 3~200mg
Aspartame 2~50mg
Micropowder silica gel 0.2~40mg
Magnesium stearate 0.5~20mg.
2, metadoxine dispersible tablet as claimed in claim 1 is characterized in that described metadoxine dispersible tablet is composed of the following components:
Metadoxine 500mg
Mannitol 250mg
Crospolyvinylpyrrolidone 50mg
Aspartame 16mg
Micropowder silica gel 24mg
Magnesium stearate 8mg.
CNB2004100359415A 2004-10-15 2004-10-15 Metaducine dispersion tablet and its preparation method Expired - Lifetime CN1301108C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNB2004100359415A CN1301108C (en) 2004-10-15 2004-10-15 Metaducine dispersion tablet and its preparation method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNB2004100359415A CN1301108C (en) 2004-10-15 2004-10-15 Metaducine dispersion tablet and its preparation method

Publications (2)

Publication Number Publication Date
CN1650862A CN1650862A (en) 2005-08-10
CN1301108C true CN1301108C (en) 2007-02-21

Family

ID=34868508

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100359415A Expired - Lifetime CN1301108C (en) 2004-10-15 2004-10-15 Metaducine dispersion tablet and its preparation method

Country Status (1)

Country Link
CN (1) CN1301108C (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL187159A0 (en) * 2007-07-03 2009-02-11 Gur Megiddo Use of metadoxine in relief of alcohol intoxication
WO2010013242A1 (en) 2008-07-29 2010-02-04 Alcobra Ltd. Substituted pyridoxine-lactam carboxylate salts
NZ597319A (en) 2009-06-25 2014-06-27 Alcobra Ltd A method for the treatment, alleviation of symptoms of, relieving, improving and preventing a cognitive disease, disorder or condition
BR112015006642B1 (en) * 2012-09-26 2022-08-02 Eurodrug Laboratories B.V PROLONGED RELEASE PHARMACEUTICAL COMPOSITION COMPRISING METHADOXINE AND PREDNISONE
CN103099794B (en) * 2013-02-19 2014-07-30 青岛正大海尔制药有限公司 Vitamin C clathrate dispersible tablet

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1359680A (en) * 2001-12-26 2002-07-24 成都康弘制药有限公司 Prescription of preparing moxapride citrate
CN1449757A (en) * 2003-04-30 2003-10-22 江西省药物研究所 Domperidone oral disintegrating tablet and preparation process thereof
CN1490006A (en) * 2003-08-20 2004-04-21 杭州容立医药科技有限公司 Melazocine masticatory and its preparation
CN1528350A (en) * 2003-09-29 2004-09-15 武汉健民中药工程有限责任公司 Dispersion tablet containing ginkgo leaf extract

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1359680A (en) * 2001-12-26 2002-07-24 成都康弘制药有限公司 Prescription of preparing moxapride citrate
CN1449757A (en) * 2003-04-30 2003-10-22 江西省药物研究所 Domperidone oral disintegrating tablet and preparation process thereof
CN1490006A (en) * 2003-08-20 2004-04-21 杭州容立医药科技有限公司 Melazocine masticatory and its preparation
CN1528350A (en) * 2003-09-29 2004-09-15 武汉健民中药工程有限责任公司 Dispersion tablet containing ginkgo leaf extract

Also Published As

Publication number Publication date
CN1650862A (en) 2005-08-10

Similar Documents

Publication Publication Date Title
CN1772011A (en) Ginkgo leaf extract composition and its prepn
CN1762357A (en) Oral medicinal formulation of moxifloxacin and its preparation method
CN1527700A (en) Compaction process for manufacture of sodium phenytoin dosage form
CN1931167A (en) Double layer osmotic pump controlled release felodipine medicine composition
CN1301108C (en) Metaducine dispersion tablet and its preparation method
CN1843458A (en) Chronic pharyngolaryngitis effervescence tablet and preparation method and its quality control method
CN100339072C (en) Methocarbamol dry mixing suspension
CN1887315A (en) Fukean dispersible tablet and preparation method thereof
CN1186051C (en) 'Huajuhong' preparation and its preparing process
CN1593634A (en) Blood nourishing, brain refreshing orally disintegrating tablet and its preparation process
CN1582928A (en) Medicinal composition and its use in treatment of diabetes
CN1679648A (en) Mailuoning injection and its preparation and quality control
CN1843343A (en) Methocarbamol dispersion tablet
CN1857588A (en) Quality control method for Xianlinggubao preparation
CN1291734C (en) Method for preparing and controlling the quality of Chinese medicinal soft capsule
CN1857385A (en) Medicine composition for treating cervical spondylosis and its preparing method
CN1891256A (en) Red sage root dispersible tablet for treating cornary heart diseae and its preparing method
CN103385862B (en) A kind of metoprolol tartrate extended release tablets and preparation method thereof
CN101057866A (en) Method for preparing 'kelike' capsule
CN1251693C (en) Chinese-western medicine compound preparation and its preparing method
CN1861106A (en) Compound isatis root effervescent tablet and its prepn. method
CN100340239C (en) Andrographolide dispersing tablets
CN1839863A (en) Diabetes-treating pharmaceutical compositions and its preparing method and uses
CN1846748A (en) Cold-treating Fupu effervescent tablet and its prepn process and quality control method
CN1259037C (en) Orally disintegrating tablet of antiviral medicine and its preparation process

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20160526

Address after: 129, room 1, building 266112, Qingdao blue bio Pharmaceutical Industrial Park, 368 Hedong Road, Hedong District, Qingdao, Shandong

Patentee after: Qingdao Pu Ruisen Pharmaceutical Technology Co., Ltd

Address before: 255400 Linzi, Shandong province people's road, No. 28 East Road, No.

Patentee before: Qidu Pharmaceutical Co., Ltd., Shandong Prov.